Study2017

Photobiomodulation with Near Infrared Light Helmet in a Pilot, Placebo Controlled Clinical Trial in Dementia Patients Testing Memory and Cognition

Berman MH, Halper JP, Nichols TW, Jarrett H, Lundy A, Huang JH

Journal of neurology and neuroscience · 113 citations

How it was studied

Design
Randomized controlled trial (classified by our AI screen)
Studied in
People
Main outcome
Health markers and function

Who paid for it

Funding
Independent funding
Government
National Institutes of Health
Government
National Institute of Neurological Disorders and Stroke
Government
NINDS NIH HHS
Grants
National Institute of Neurological Disorders and Stroke (R01-NS-067435); National Institutes of Health (R01 NS067435)

Based on 3 listed funder(s).

Publication

Published
2017-01-01 · J Neurol Neurosci · vol. 08 · issue 01
Cited
172 citations · more than 98% of similar papers · 7.7× the field average
Impact
Top 10% most cited in its field
References
20 works
Access
Free to read
Research areas
Laser Applications in Dentistry and Medicine · Photoreceptor and optogenetics research · Planarian Biology and Electrostimulation
Keywords
Dementia, Medicine, Clinical trial, Placebo, Cognitive decline, Neuroscience, Disease, Internal medicine, Psychology, Pathology

6 authors

From US

  • Marvin H. BermanQuietmind Foundation
  • James P. HalperQuietmind Foundation
  • Trent W Nichols · correspondingQuietmind Foundation
  • Hugh JarrettQuietmind Foundation
  • Alan LundyQuietmind Foundation
  • Jason Haitao Huang · correspondingBaylor Scott & White Medical Center - Temple; Quietmind Foundation

Abstract

Alzheimer's disease (AD) is a common, chronic expensive debilitating neurodegenerative disease with no current treatments to prevent the physical deterioration of the brain and the consequent cognitive deficits. The current pathophysiology of Alzheimer's disease is the accumulation of neurofibrillary tangles (NFTs) of hyperphosphorylated tau protein and amyloid-beta (Aβ) plaques. Antibody therapy of Tau and Amyloid beta, vaccines and other methods to decrease Tau and or Amyloid have not been successful after considerable pharmaceutical and biotech efforts. For example, Eli Lilly announced a major change to its closely watched clinical trial for the Alzheimer's drug solanezumab which failed to reach statistical significance. Recently, a report on animal models using photomodulation with near infrared light to treat AD pathology in K369I tau transgenic model (K3) l engineered to develop neurofibrillary tangles, and the APPs/PSEN1dE9 transgenic model (APP/PS1) to develop amyloid plaques. Mice were treated with NIR 20 times over a four-week period and NIR treatment (600-1000 nm) was associated with a reduction in the size and number of amyloid-β plaques in the neocortex and hippocampus. We now report a small pilot double blind, placebo-controlled trial (n=11) 6 active, 3 controls and 2 dropouts assessing the effect of 28 consecutive, sixminute transcranial sessions of near infrared (NIR) stimulation using 1060-1080 nm light emitting diodes. Subjects were independently diagnosed with dementia conducted in an outpatient behavioral healthcare clinic. IRB approval was obtained through the Quietmind Foundation's institutional review Board (IRB). Results showed changes in executive functioning; clock drawing, immediate recall, praxis memory, visual attention and task switching (Trails A&B) as well as a trend of improved EEG amplitude and connectivity measures. Neuroplasticity has also been reported with NIR light stimulation and mitochondrial enhancement.

Abstract via Europe PMC. Copyright remains with the authors or publisher.

Community trust

Loading…

How much do you trust this study's findings?

0 · not at all10 · completely

Comments

Sign in to rate, comment on or flag this study.Sign in

Something wrong here?

Flag this study if its information, labels or funding look wrong. An editor reviews every flag.

Sign in to rate, comment on or flag this study.Sign in

Educational information about published research. Not medical advice, and not a recommendation to start or stop anything.